LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
As previously announced, members of the management team of Ligand Pharmaceuticals Incorporated (“Ligand”) presented at Ligand’s Analyst Day event in New York, New York on March 12, 2019. The slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and will also be available under the “Investors – News and Events” section of Ligand’s website at www.ligand.com.
The information in this Current Report on Form 8-K, including the presentation slides attached hereto as Exhibit 99.1, is being furnished to this Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
Description |
|
Slide Presentation – dated March 12, 2019. |
LIGAND PHARMACEUTICALS INC Exhibit
EX-99.1 2 a2019adpresentationvfina.htm EXHIBIT 99.1 a2019adpresentationvfina 2019 Analyst Day Exhibit 99.1 March 12,…
To view the full exhibit click here
About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.
